Estado actual del tratamiento de las metástasis hepáticas del cáncer colorrectal

Medicina Clinica

Volumn 114, Issue 13, 2000, Pages 506-510

  Cubillo, A ^a   De Castro, J ^b   Feliu, J ^b   Gonzalez Baron M ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; LIVER METASTASIS; LIVER RESECTION; PROGNOSIS; REVIEW;

CARCINOMA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 0034621023     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71346-7     Document Type: Article

References (79)

1. Schottenfeld D, Winawer SJ. Cancer: epidemiology and prevention. En: Schottenfeld D, Fraumeni JF Jr, editores. Filadelfia: WB Saunders, 1982; 703-707.
2. Abad A, Font A, Piṅol M. Analysis of the clinical prognostic factors in colorectal cancer patients undergoing curative resection. Proc Am Soc Clin Oncol 1993; 12: 226.
3. Feliu J, Gorzalez Barȯn M. Cáncer de colon y recto: tratamiento de la enfermedad avanzada. En: Gȯnzalez Barȯn, editor. Oncologia clinica. Fundamentos. Madrid: Mc Graw-Hill, 1998; 222.
4. Gilbert HA, Kagan AR. Metastases: incidence, detection, and evaluation without histologic confirmation. En: Weiss L, editor. Fundamental aspects of metastasis Amsterdam: North-Holland, 1976; 385-406.
5. Schulz W, Hagen C, Hort W. The distribution of liver metastases from colonic cancer: a cuantitative postmortem study. Virchow Arch 1985; 406: 279.
6. Kemeny MM, Goldberg D, Beatly D. Results of a prospective randomized trial of continuos regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorrectal primaries. Cancer 1986; 57: 492-498.
7. Van Oojein B, Wiggers T, Meijer S. Hepatic resection from colorrectal metastases in the Netherlands - A multiinstitucional 10-year study. Cancer 1992; 57: 492-498.
8. Cady B, Mc Dermott W. Major hepatic resection from metachronus metastases from colon cancer. Ann Surg 1985; 201: 204-209.
9. Daly JM, Kemeny NE. Metastasic cancer to the liver. En: De Vita, editor. Principles and practice of oncology. Vol. 2. Filadelfia: Lippincott-Raven, 1997; 2553.
10. Reing JW, Dwyer AJ, Miller DL. Liver metastasis detection:comparative sensitivities of MR imaging and CT scaning. Radiology 1987; 162:43.
11. Daly J, Nancy M, Kemeny E. Metastasic Cancer to the liver. En: De Vita, editor. Principles and practice of oncology. Vol. 2. Filadelfia: Lippincott-Raven, 1997; 2554-2555.
12. Moertel CG, Fleming TR, Macdonald JS. An evaluation of the carcino-embryonic (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943-948.
13. DeNardo GL. Status of radioinmunoimaging and radioinmunotherapy for cancer. ASCO, 1999. Atlanta: Educational Book, 1999; 472.
14. Flamen P, Stroobants S, Van Cutsem E. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose in recurrent colorectal cancer. J Clin Oncol 1999; 17: 894-901.
15. Mori M, Mimori K, Ueo H. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 1998; 16: 128-132.
16. Woodington GH, Waugh JM. Results of resection of metastasic tumors of the liver. Am J Surg 1963; 105: 24-29.
17. Sȧenz N, Cady B, Mcdermott W, Steele G. Experience with colorrectal carcinoma metastasic to the liver. Surg Clin North Am 1989; 69: 361-169.
18. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Istrup DW. The natural history of hepatic metastases from colorectal cancer. Ann Surg 1984; 199: 502-508.
19. Stangl R, Altendorf-Hofmann A, Charnely RM, Scheele J. Factors influencing the natural history of colorrectal liver metastases. Lancet 1994; 343: 1405-1410.
20. McMasters KM, Roh MS. Surgical treatment of hepatic metastases. En Lotze MT, Rubin JT, editores: regional therapy of advanced cancer: Filadelfia: Lippincott-Raven Publishers, 1997; 99-117.
21. Petteval J, Morgenthaler F. Protacted arterial chemotherapy of liver tumors: an experience of 107 cases over a 12 years period. Prog Clin Cancer 1978; 7: 217-220.
22. Wood CB, Gilis CR, Blungart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 1976; 2: 258-262.
23. Bengstsson G, Carlsson G, Hafstrom L, Johnsson PE. Natural history of patients with treated liver metastases from colorectal cancer. Am J Surg 1981; 141: 586-594.
24. August DA, Sugarbaker PH. Hepatic resection of colorectal metastases. Ann Surg 1985; 201: 210-216.
25. Finan PJ, Marshall RJ, Cooper EH, Giles JR. Factors affecting survival in patients presenting with syncchronus hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 1985; 72: 373.
26. Lahr CJ, Soong SJ, Clond G. A multifactorial analysis of prognostic factors in patients with liver metastases. Am J Surg 1978; 135: 81-86.
27. Adson MA. Diagnosis and surgical treatment of primary and secondary solid tumors in the adult. Surg Clin North Am 1981; 61: 1181-1187.
28. Lokich JJ. Primary and metastasic liver cancer. Semin Oncol 1983; 10: 227-233.
29. Fong Y, Cohen AM, Fortner JG. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946.
30. Borner M. Quimioterapia neoadyuvante para las metástasis hepáticas irresecables del cȧncer colorrectal: ¿ es demasiado bueno para ser verdad? Ann Oncol 1999; 8: 842-845.
31. Earlam S, Glover C, Fordy C. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 1996; 14: 171-175.
32. Castro J, Feliu J, Gónzalez Barón M. Estado actual del tratamiento regional de las metástasis hepáticas del carcinoma colorrectal. Rev Clin Esp 1995; 95: 565-566.
33. Van der Meer TJ, Callery MP, Meyers WC. The approach to the patient with single and multiple liver metastasis, pulmonary metastases, and intraabdominal metastases from colorectal carcinoma. Hemato/Oncol Clin North Am 197; 11: 759-777.
34. Fong Y, Cohen AM, Fortner JG. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946.
35. Hughes KS, Simon R, Songhorabodi S. Resection of the liver for colorectal carcinoma metastases: A multi-institucional study of patters of recurrence. Surgery 1986; 100: 278-284.
36. Breedis C, Young C. The blood supply of neoplasm in the liver. Am J Pathol 1954; 30: 969-973.
37. Knol JA, Walker SC, Roberston JM. Incorporation of 5-Bromo-2′-dexyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Res 1995; 55 3687-3691.
38. Weiss L. Metastasic inefficiency and regional therapy for liver metastases from colorectal carcinoma. Reg Cancer Treat 1989; 2: 77-82.
39. Weiss L, Grudmann E, Torhorst J. Hematogenous metastasic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986; 150: 195-201.
40. Sigurdson ER, Ridge JA, Kemeny N. Tumor and liver drug uptake following artery and portal vein infusion. J Clin Oncol 1987; 5: 1836-1840.
41. Khöne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM. Chemotherapeutics strategies in metastasic colorectal cancer:An overview of current clinical trials. Sem Oncol 1992; 19 (Supl 3): 105-125.
42. Meta-analysis Group In Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-258.
43. Sastre J, Díaz Rubio E. Tratamiento médico del cáncer de colon. Ann Oncol 1999; 9 (Supl 2): 161-178.
44. Doria MI, Shepard KV, Levin B. Liver pathology following hepatic arterial infusion chemotherapy. Cancer 1986; 58: 855-861.
45. Doria MI, Doria LK, Faintuch J, Levin B. Gastric mucosal injury after nepatic arterial infusion chemotherapy with floxuridine. Cancer 1994; 73: 2042-2047.
46. Vaughn D, Daly J, Weintraub F. A pilot trial of intrahepatic fludeoxyuridine (FUDR) & sistemyc 5-Fluoracil (%-FU) plus leucovorin (LV) in patients with colorectal cancer (CRC). Proc Am Soc Clin Oncol 1994; 13: 323-328.
47. Hunt TM, Flowerdew AD, Birch SJ, Williams JD, Mulle MA, Taylor I. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluoracil and degradable starch microspheres for colorectal liver metatases. Br J Surg 1990; 77: 779-785.
48. Stagg R, Venook A, Chase J, Frye J, Ring E, Hohn D. Chemoembolization of primary and metastasic liver tumors. Reg Cancer Treat 1992; 1: 53-60.
49. Livraghi T, Vettori C, Lazzaroni S. Liver metastases: results of percutaneos ethanol injection in 14 patients. Radiology 1991; 179: 709-712.
50. Sansone F, Carrieri V. Percutaneous ethanol injection with US guidance in patients with hepatocellular carcinoma or liver metastases [resumen]. Radiology 1992; 185: 236-239.
51. Daly J, Nancy M, Kemeny E. Metastasic cancer to the liver. En: De Vita, editor. Principles and practice cf oncology. Vol. 2. Filadelfia: Lippincott-Raven, 1997; 2567-2568.
52. Giovannini M, Seitz JF. Ultrasound guided percutaneous injection of small liver metastases. Cancer 1994; 73: 294-299.
53. Prasad B, Lee M, Hendrickson FR. Irradiation of hepatic metastases. J Radiat Oncol Biol Phys 1977; 2: 129-135.
54. Lawrence TS, Kessler ML, Roberston JM. Conformal high dose radiation plus intraarterial hepatic floxuridine for hepatic cancer. Oncology 1993; 7: 51-56.
55. Dritschilo A, Harter K, Thomas D. Intraoperative radiation therapy of hepatic metastases: technical aspects and report of a pilot study. Int J Radiat Oncol Biol Phys 1988; 14: 1007-1011.
56. Amstrong JG, Anderson LL, Harrison LB. Treatment of liver metastases from colorectal cancer with radioactive implants. Cancer 1994; 73: 1800-1804.
57. Ravinukar T, Kane R, Cady B. Hepatic criosurgery with intraoperative ultrasound monitoring for metastatic colon carcinoma. Arch Surg 1987; 122: 403-409.
58. Onik G, Rubinsky B, Zemel R. Ultrasound-guided hepatic cryosurgery in the treatment of metastasic colon carcinoma. Preliminary resulta. Cancer 1991; 67: 901-906.
59. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Ed nb 1998; 43: 141-154.
60. Advanced Colorectal Cancer Meta-Aralysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluoracil by methotrexate in metastasic colorectal cancer. J Clin Oncol 1994; 12: 960-969.
61. Advanced colorectal cancer meta-analysis Project. Modulation of fluoraci by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
62. Borner MM, Castiglione M, Bacchi M. The impact of adding low-dose leucovorin to monthly 5-fluoracil in advanced colorectal carcinoma: results of a phase III trial. Ann Oncol 1998; 9: 535-541.
63. Poon MA, O'Connell MJ, Wieand HS. Biochemical modulation of fluoracil with leucovorine: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-1972.
64. Saltz LB, Locker PK, Pirotta N. Weekly irinotecan (CPT-11), leucovorin (LV), and fluoracil (FU) is superior to daily 5 LV/5FU in patients with previously untreated metastasic colorectal cancer as front line chemotherapy [resumen 899]. Proc ASCO 1999; 18: 233.
65. Douillard JY, Cunnigham D, Roth AD. A randomized phase III trial comparing irinotecan + 5FU/folinis acid to tha same schedule of 5FU/FA in patients with metastasic colorectal cancer as front line chemotherapy [resumen 899]. Proc ASCO 1999; 18: 233.
66. De Gramont A, Figer A, Seymour M. A randomized trial of leucovorin and 5-fluoracil with or without oxaliplatin in advanced colorectal cancer [resumen 985]. Proc ASCO 1999; 17: 257.
67. Giaccheti S, Itzhak M, Gruia G. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluoracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
68. Lévi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluoracilo, and folinis acid in metastasic colorectal cancer. Lancet 1997; 350: 681-686.
69. Levi F, Misset JL, Brienza. A chronopharmacologic phase II clinical trial with 5-fluoracil, flolinic acid and oxaliplatin using and ambulatory multi-channel programmable pump: high antitumor effectiveness against metastasic colorectal cancer. Cancer 1992; 69: 893-900.
70. Bertheaull-Cvitkovic F, Jami A. Bi-weekly intensified ambulatory chrono-modulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients wth metastasic colorectal cancer. J Clin Oncol 1996; 14: 2950-2958.
71. De Matteo RP, Minnard EA, Kemeny N. Outcome after resection of both liver and lung metastases in patients with colorectal cancer [resumen 958]. Proc Am Soc Clin Oncol 1999; 18: 249.
72. Moertel CG, Fleming TR, Macdonald JS. Flucracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Am Intern Med 1995; 122: 321-326.
73. Wolmark N, Rockette H, Fisher B. The benefit of leucovorin modulated fluoracil as posoperative adjuvant theraoy for primary colon cancer: resuits from NSABP protocol C-03. J Clin Oncol 1993; 11: 1879-1887.
74. Internacional Multicentre Pooled Analysis ol colon Cancer Trials (IMPACT) Investigators. Efficacy of adyuvant fluoracili and folinic acid in colon cancer. Lancet 1995; 345: 939-944.
75. Goldberg RM. Liver-limited colorectal cancer metastases: specific strategies for a special patient subset. San Francisco: Fall Educational Book, 1999; 73.
76. Kemeny MM, Goldberg D, Beatty JD. Results of a prospectively randomized trial of continous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 1986; 57: 492-498.
77. Safi F, Bittner R, Roscher R. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continous intraarterial versus continues intraarterial/intravenous therapy). Cancer 1989; 64: 379-387.
78. Kemeny MM, Adak S, Lipsitz S. Results of the intergroup Eastern Cooperative Oncology (ECOG) and Southwest Oncology Group (SWOG) prospective randomized study of surgery alone versus continous hepatic artery infusion of FUDR and continuos systemic infusion of%-FU after hepatic resection for colorectal liver metastases [resumen 1012]. Proc Am Soc Clin Oncol 1999; 18: 264.
79. Kemeny N, Cohen A, Huang Y. Randomized study of hepatic arterial infusion (HAI) and sistemic chemotherapy (SYS) versus SYS alone as adjuvant therapy after resection of hepatic metastases from colorectal cancer [resumen 1011]. Proc Am Soc Clin Oncol 1999; 18: 263.